Skip Navigation
Skip to contents

ICDM 2022

Sponsored sessions

Plenary lectures Main Symposia Committee sessions Research group sessions Special sessions Corporate symposia
Sponsored session 1 :
New horizons in type 2 diabetes care with oral GLP1-RA
Sponsored by Novo Nordisk		 17:00~18:00 / Thursday 6 October
Convention Hall A, 4F
Chairman:Eun Seok Kang
Sung Hee Choi
Seoul National University, Korea
 SS1-1Where are we in type 2 diabetes management from oral to injection?
Juris Meier
Augusta Clinic Bochum, Germany
 SS1-2Innovations in the GLP-1 RA landscape
Sponsored session 2 Sponsored by AstraZeneca 17:00~18:00 / Thursday 6 October
Convention Hall B, 4F
Chairman:Sang Ah Chang
Changhee Jung
University of Ulsan, Korea
 SS2-1Diabetes and chronic complication care and management from SGLT2i
Sang Youl Rhee
Kyung Hee University, Korea
 SS2-2Cardiometabolic benefit beyond glycemic control for T2D
Jun Hwa Hong
Eulji University, Korea
 SS2-3Overcoming therapeutic inertia: achieving optimal targets
Sponsored session 3 Sponsored by Dong-A ST 17:00~18:00 / Thursday 6 October
Convention Hall C, 4F
Chairman:Kee-ho Song
Ji Hye Huh
Hallym University, Korea
 SS3-1Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease
Sangmo Hong
Hanyang University, Korea
 SS3-2Cardiovascular outcome from big data study
Sponsored session 4 Sponsored by BI-LLY 15:30~16:30 / Saturday 8 October
Convention Hall A, 4F
Chairman:Chul Sik Kim
Javed Butler
Baylor Scott and White Research Institute, USA
SS4-1EASD/ESC symposium: new perspectives on heart function and failure in diabetes
Christoph Wanner
University Hospital Würzburg, Germany
 SS4-2New insights for prevention of microvascular complications
Sponsored session 5 Sponsored by Handok 15:30~16:30 / Saturday 8 October
Convention Hall B, 4F
Chairman:Junghyun Noh
Young Min Cho
Seoul National University, Korea
 SS5-1Optimal personalized treatment of T2DM based on recent evidence
Seung-Hwan Lee
The Catholic University of Korea, Korea
 SS5-2New issues of SGLT-2 inhibitors
So Hun Kim
Inha University, Korea
 SS5-32022 ADA/ENDO hot topic: should obesity be a primary target for type 2 diabetes?
Sponsored session 6 Sponsored by Daewoong Pharmaceutical 15:30~16:30 / Saturday 8 October
Convention Hall C, 4F
Chairman:Chul-Hee Kim
Soo Lim
Seoul National University, Korea
 SS6-1SGLT2 inhibitor: beyond the glucose-lowering effect
Suk Chon
Kyung Hee University, Korea
 SS6-2Efficacy and safety of SGLT2 inhibitor for Korean T2DM patients